Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma

Overview of attention for article published in Hepatology, June 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (56th percentile)

Mentioned by

twitter: 5 X users

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 5 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 23,863 followers.

RT @HEP_Journal: Lim M et al. Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma #LiverTwitter https:…

10 Dec 2023

Reply Repost Favourite

RT @HEP_Journal: Lim M et al. Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma #LiverTwitter https:…

09 Dec 2023

Reply Repost Favourite

Lim M et al. Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma #LiverTwitter https://t.co/LZj2Vojtbh https://t.co/NlAuC5CPVI

08 Dec 2023

Reply Repost Favourite

Congratulations to Dr. David Hsieh on your public disclosure, “Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma.” We’re proud to facilitate your access to data #ClinicalResearch https://t.co/rzyYCZY3Dy

07 Sep 2023

Reply Repost Favourite

RECIST ORR as an appropriate signal-finding measure for OS? Surrogate and modified endpoints for immunotherapy in... : Hepatology https://t.co/jRA6c0Geef

16 Jun 2023

Reply Repost Favourite